We’re thrilled to announce Dr. Ina Liko has joined RxGenomix as our Director of Clinical Pharmacogenomic Operations. She brings a wealth of clinical knowledge to the team and will be tasked with advancing our mission of making a real difference in how PGx gets applied to patient care.
Dr. Brad Tice, RxGenomix founder and CEO, sees interest in PGx adoption growing in the market and is excited to be adding to our clinical team. “RxGenomix was created specifically to improve and accelerate the application of the science of pharmacogenomics to patient care, and there’s no doubt we’re at a tipping point in market adoption. Dr. Liko brings a wealth of knowledge and experience that will help us lead the way in expanding the clinical application of PGx to optimize medication use to improve people’s lives and reduce healthcare costs.”
Dr. Liko received her Doctor of Pharmacy degree from the University of Illinois at Chicago, where she first saw the enormous potential of PGx to advance patient care, and decided to make that her professional focus. She went on to complete a clinical residency program at Monroe Clinic where her research project was focused on the implementation of PGx. After this initial exposure to clinical application, she gained experience in implementing it in a larger scale by completing a fellowship in the Clinical Implementation of Pharmacogenomics at the University of Colorado, where she was exposed to a systematic approach of implementing it across multiple therapeutic classes. Since completing her fellowship, she has been serving as a Medical Science Liaison.
Dr. Liko will be presenting weekly webinars on how to put PGx to work for patients through our Clinical Pearls series. Watch for announcements and reminders on LinkedIn and Facebook or contact us at [email protected] for more details.